Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1964 1
1965 3
1966 2
1967 7
1968 2
1970 2
1972 1
1974 3
1975 3
1976 4
1977 1
1978 7
1980 1
1981 5
1982 3
1983 2
1984 2
1985 3
1986 3
1987 1
1988 4
1989 3
1990 3
1991 1
1992 3
1993 2
1994 2
1995 1
1996 2
1997 1
1998 2
1999 3
2000 1
2001 1
2002 1
2005 1
2006 1
2009 2
2011 1
2012 1
2013 2
2014 3
2015 2
2016 3
2017 5
2018 4
2019 2
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

109 results
Results by year
Filters applied: . Clear all
Page 1
[Pyelonephritis].
Takayasu S, Terawaki Y. Takayasu S, et al. Among authors: terawaki y. Naika. 1967 Jun;19(6):1129-32. Naika. 1967. PMID: 4865503 Review. Japanese. No abstract available.
Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice.
Takahashi H, Nomiyama T, Terawaki Y, Horikawa T, Kawanami T, Hamaguchi Y, Tanaka T, Motonaga R, Fukuda T, Tanabe M, Yanase T. Takahashi H, et al. Among authors: terawaki y. Biochem Biophys Rep. 2019 Apr 19;18:100640. doi: 10.1016/j.bbrep.2019.100640. eCollection 2019 Jul. Biochem Biophys Rep. 2019. PMID: 31032431 Free PMC article.
Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F).
Terawaki Y, Iwaya C, Nomiyama T, Shimono D, Horikawa T, Fujimura-Tanaka Y, Shigeoka T, Hamanoue N, Motonaga R, Tanabe M, Yanase T, Kawanami D; Collaborators in the Repaglinide Glucose Oscillation Study in Fukuoka (REGO-F) trial. Terawaki Y, et al. Diabetol Int. 2020 Feb 14;11(3):274-282. doi: 10.1007/s13340-020-00426-w. eCollection 2020 Jul. Diabetol Int. 2020. PMID: 32802709 Free PMC article.
[Control of plasmid replication].
Terawaki Y. Terawaki Y. Nihon Saikingaku Zasshi. 1986 Mar;41(2):513-25. doi: 10.3412/jsb.41.513. Nihon Saikingaku Zasshi. 1986. PMID: 2426479 Review. Japanese. No abstract available.
Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
Nomiyama T, Shimono D, Horikawa T, Fujimura Y, Ohsako T, Terawaki Y, Fukuda T, Motonaga R, Tanabe M, Yanase T; Collaborators of Fukuoka Study of Ipragliflozin (FUSION) trial. Nomiyama T, et al. Among authors: terawaki y. Endocr J. 2018 Aug 27;65(8):859-867. doi: 10.1507/endocrj.EJ18-0022. Epub 2018 May 26. Endocr J. 2018. PMID: 29806620 Free article. Clinical Trial.
Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.
Tsutsumi Y, Nomiyama T, Kawanami T, Hamaguchi Y, Terawaki Y, Tanaka T, Murase K, Motonaga R, Tanabe M, Yanase T. Tsutsumi Y, et al. Among authors: terawaki y. PLoS One. 2015 Oct 6;10(10):e0139709. doi: 10.1371/journal.pone.0139709. eCollection 2015. PLoS One. 2015. PMID: 26439622 Free PMC article.
Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth.
Nomiyama T, Kawanami T, Irie S, Hamaguchi Y, Terawaki Y, Murase K, Tsutsumi Y, Nagaishi R, Tanabe M, Morinaga H, Tanaka T, Mizoguchi M, Nabeshima K, Tanaka M, Yanase T. Nomiyama T, et al. Among authors: terawaki y. Diabetes. 2014 Nov;63(11):3891-905. doi: 10.2337/db13-1169. Epub 2014 May 30. Diabetes. 2014. PMID: 24879833 Free article.
109 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page